

September 1, 2020



Resmed

ResMed Debuts AirTouch N20 Foam CPAP Mask, Its Softest Nasal Mask Ever

- *ResMed's first nasal memory foam cushion enhances patients' comfort and convenience, doesn't need cleaning when replaced on an appropriate schedule*
- *AirTouch N20 is the latest offering in ResMed's line of easy-to-use, convenient, and more comfortable masks*

SAN DIEGO--(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD) announced today the launch of its AirTouch N20 nasal mask, the company's first CPAP nasal mask with a memory foam cushion and softest nasal mask ever.

This press release features multimedia. View the full release here:

<https://www.businesswire.com/news/home/20200901005249/en/>



ResMed AirTouch N20, nasal CPAP mask with UltraSoft memory foam cushion (Photo: Business Wire)

AirTouch N20 uses the same patented UltraSoft memory foam cushion as the full face AirTouch F20 mask introduced in 2017. Both adapt to the curves and contours of each face, creating a soft, personalized fit designed to increase comfort and CPAP adherence. In a clinical study, 90 percent of CPAP users gave the UltraSoft foam

cushion a high rating for comfort – a 4 or 5 out of 5.¹

This unique comfort also comes with added convenience: The foam cushion doesn't require cleaning when replaced on an appropriate schedule.

Most important, AirTouch N20's comfort and convenience can help increase patient

satisfaction, adherence, and benefit from long-term therapy.

Additional features include:

- Quick-release elbow allows patients to easily disconnect from tubing without removing their mask, and magnetic clips guide the headgear to the frame quickly and easily
- AirFit N20's mask frame fits both AirFit N20 silicone and AirTouch N20 memory foam cushions, allowing clinicians to conveniently switch between the two during fittings or send patients home with both to see which cushion type they prefer
- A seal designed for therapy pressures up to 30 cm H₂O

"CPAP therapy should be simple, comfortable, and easy to use – and AirTouch N20 delivers on all three," said Jim Hollingshead, ResMed president of Sleep and Respiratory Care. "The foam cushion is uniquely comfortable, adapts to give everyone a personalized fit, and doesn't need cleaning. It's ideal for nasal CPAP users and their providers."

AirTouch N20 is the latest in ResMed's family of innovative CPAP masks, connected devices, and digital health technologies for helping millions with sleep apnea, COPD, and other chronic diseases sleep, breathe, and live better.

AirTouch N20 is now available in the U.S., Canada, and most of Europe, with Asia-Pacific launches planned for later this year. For more information, visit [ResMed.com/AirTouchN20](https://www.resmed.com/AirTouchN20).

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit [ResMed.com](https://www.resmed.com) and follow @ResMed.

1 ResMed clinical study: ResMed AirTouch F20 full face mask evaluation of facial marks. A total of 29 evaluable CPAP users trialed the mask at home for 30 nights in place of their current mask in which they were experiencing facial marks. Conducted from September 11, 2017 to February 19, 2018. (AirTouch N20 uses the same UltraSoft™ memory foam cushion technology as AirTouch F20).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20200901005249/en/>

For media

Jayne Rubenstein

+1 858.836.6798

news@resmed.com

For investors

Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

Source: ResMed